CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Explore Esperion Therapeutics's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Jul 31, 2025
Patent NumberGrant DateTitleTotal Oppositions
Nov 1, 2023Fixed Dose Combinations Comprising Etc1002 And One Or More Statins For Treating Or Reducing Cardiovascular Risk6

Top competitors of Esperion Therapeutics

List of top competitors of Esperion Therapeutics based on patent oppositions.